Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NSPR
NSPR logo

NSPR News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NSPR News

InspireMD to Release Q4 and Full Year 2025 Financial Results

1d agoNewsfilter

InspireMD Publishes Positive CREST-2 Data Confirming Efficacy of Carotid Stenting

Nov 24 2025Newsfilter

InspireMD to Attend the 37th Annual Healthcare Conference Hosted by Piper Sandler

Nov 19 2025Newsfilter

InspireMD, Inc. Reports Wider Q3 Loss, Yet Surpasses Expectations

Nov 04 2025NASDAQ.COM

InspireMD Names Peter Soukas as Chief Medical Officer

Nov 03 2025NASDAQ.COM

Parkman Healthcare Increases Investment in InspireMD to Support Carotid Innovation

Sep 22 2025Yahoo Finance

Biobeat Technologies Appoints Raymond W. Cohen as Board Chairman

Aug 21 2025Newsfilter

RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

Aug 04 2025Newsfilter

NSPR Events

01/20 09:10
InspireMD Approves Inducement Grants of 36,118 Shares to New Employee
InspireM announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one new non-executive employee in the aggregate amount of 36,118 shares of restricted stock outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted under the InspireMD's 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4). The restricted stock vests over a three-year period, with one-third vesting on the first anniversary of the grant and the remainder vesting in two equal installments on the second and third anniversaries of the grant date, subject to continued employment with InspireMD as of such vesting dates.
01/12 09:20
InspireMD C-GUARDIANS Trial Results Published, 30-Day DSMI Rate at 0.95%
InspireMD announced that results from the Company's C-GUARDIANS trial have now been published in the Journal of the American College of Cardiology. The data demonstrate the safety and efficacy of carotid artery stenting, CAS, with the Company's MicroNet covered stent in patients with asymptomatic carotid stenosis. "The C-GUARDIANS results are exceptional, with a 30-day DSMI rate of just 0.95% and a one-year ipsilateral stroke rate of 1.93%, which are the lowest reported in high-risk patients," said Dr. Chris Metzger, M.D., Interventional cardiologist and endovascular interventionalist at Ballad Health, and lead investigator of the C-GUARDIANS trial. "What's particularly noteworthy is that we achieved these outcomes in a cohort that included 25% symptomatic patients, a group traditionally at elevated risk. The data make a compelling case for the CGuard Prime's MicroNet(TM) technology as a potential next-generation standard of care."

NSPR Monitor News

No data

No data

NSPR Earnings Analysis

No Data

No Data

People Also Watch